Promega's OncoMate MSI system cleared by FDA

2019 05 22 19 44 5254 Dna Red Laser 400

Promega announced that its OncoMate microsatellite instability (MSI) Dx Analysis System has been cleared by the U.S. Food and Drug Administration (FDA) for use in labs in the U.S.

With the FDA clearance, the company said oncologists and pathologists in the U.S. can now access the IVD test that screens for Lynch syndrome in patients with colorectal cancer.

Page 1 of 7
Next Page